JP2020517262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517262A5 JP2020517262A5 JP2019556941A JP2019556941A JP2020517262A5 JP 2020517262 A5 JP2020517262 A5 JP 2020517262A5 JP 2019556941 A JP2019556941 A JP 2019556941A JP 2019556941 A JP2019556941 A JP 2019556941A JP 2020517262 A5 JP2020517262 A5 JP 2020517262A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- antibody
- less
- extracellular domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 238000000034 method Methods 0.000 claims 11
- 102000004388 Interleukin-4 Human genes 0.000 claims 10
- 108090000978 Interleukin-4 Proteins 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 10
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 claims 9
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 claims 9
- 102000003816 Interleukin-13 Human genes 0.000 claims 9
- 108090000176 Interleukin-13 Proteins 0.000 claims 9
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 7
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 7
- 241000283073 Equus caballus Species 0.000 claims 5
- 241000282326 Felis catus Species 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000007781 signaling event Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023028068A JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488509P | 2017-04-21 | 2017-04-21 | |
| US62/488,509 | 2017-04-21 | ||
| PCT/US2018/028507 WO2018195388A1 (en) | 2017-04-21 | 2018-04-20 | Il4/il13 receptor molecule for veterinary use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028068A Division JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517262A JP2020517262A (ja) | 2020-06-18 |
| JP2020517262A5 true JP2020517262A5 (https=) | 2021-05-27 |
| JP7657548B2 JP7657548B2 (ja) | 2025-04-07 |
Family
ID=63856393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556941A Active JP7657548B2 (ja) | 2017-04-21 | 2018-04-20 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| JP2023028068A Active JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023028068A Active JP7776461B2 (ja) | 2017-04-21 | 2023-02-27 | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11970526B2 (https=) |
| EP (1) | EP3612555A4 (https=) |
| JP (2) | JP7657548B2 (https=) |
| KR (2) | KR20200006528A (https=) |
| CN (1) | CN110770250B (https=) |
| AU (2) | AU2018254542B2 (https=) |
| BR (1) | BR112019021812A2 (https=) |
| CA (1) | CA3059731A1 (https=) |
| MX (1) | MX2019012570A (https=) |
| NZ (1) | NZ757956A (https=) |
| WO (1) | WO2018195388A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| US11970526B2 (en) | 2017-04-21 | 2024-04-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| BR112020002871A2 (pt) * | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| BR112022021204A2 (pt) * | 2020-04-22 | 2022-12-06 | Kindred Biosciences Inc | Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra |
| EP4165066A4 (en) * | 2020-06-12 | 2024-08-14 | Beijing Vdjbio Co., Ltd. | FUSION POLYPEPTIDE |
| MX2024002149A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Proteinas de fusion para tratar la dermatitis atopica. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US7083949B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| PT1141286E (pt) | 1998-12-14 | 2007-01-31 | Genetics Inst Llc | Cadeia de receptores de citocina |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| WO2001077332A2 (en) | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| WO2005032399A2 (en) | 2003-05-30 | 2005-04-14 | The Regents Of The University Of California | Il4 receptor antagonists for horse, dog and cat |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AU2005219837A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| CN1922204A (zh) | 2004-02-27 | 2007-02-28 | 瑞泽恩制药公司 | Il－4/il－13特异性的多肽和其治疗应用 |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| EP2674440B1 (en) * | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| WO2008073463A2 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| WO2009061911A1 (en) * | 2007-11-06 | 2009-05-14 | Wyeth | Assays and methods for evaluating multimeric complexes |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| ES2710384T3 (es) * | 2011-12-13 | 2019-04-24 | Pieris Pharmaceuticals Gmbh | Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores |
| EP2850093B1 (en) * | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| AU2016239858B2 (en) | 2015-04-02 | 2021-07-01 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| EA201890391A1 (ru) * | 2015-07-29 | 2018-08-31 | НАНОТИКС, ЭлЭлСи | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| US11970526B2 (en) | 2017-04-21 | 2024-04-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| BR112022021204A2 (pt) | 2020-04-22 | 2022-12-06 | Kindred Biosciences Inc | Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra |
-
2018
- 2018-04-20 US US16/605,356 patent/US11970526B2/en active Active
- 2018-04-20 KR KR1020197032241A patent/KR20200006528A/ko not_active Ceased
- 2018-04-20 EP EP18788175.0A patent/EP3612555A4/en active Pending
- 2018-04-20 BR BR112019021812-2A patent/BR112019021812A2/pt unknown
- 2018-04-20 WO PCT/US2018/028507 patent/WO2018195388A1/en not_active Ceased
- 2018-04-20 CA CA3059731A patent/CA3059731A1/en active Pending
- 2018-04-20 MX MX2019012570A patent/MX2019012570A/es unknown
- 2018-04-20 KR KR1020257012785A patent/KR20250057131A/ko active Pending
- 2018-04-20 JP JP2019556941A patent/JP7657548B2/ja active Active
- 2018-04-20 CN CN201880041160.7A patent/CN110770250B/zh active Active
- 2018-04-20 AU AU2018254542A patent/AU2018254542B2/en active Active
- 2018-04-20 NZ NZ757956A patent/NZ757956A/en unknown
-
2023
- 2023-02-27 JP JP2023028068A patent/JP7776461B2/ja active Active
- 2023-03-20 AU AU2023201726A patent/AU2023201726B2/en active Active
-
2024
- 2024-03-27 US US18/617,972 patent/US20240270820A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517262A5 (https=) | ||
| JP7277370B2 (ja) | 獣医用抗ｉｌ－３１抗体 | |
| JP2020531002A5 (https=) | ||
| Silacci et al. | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency | |
| Gearing et al. | A fully caninised anti-NGF monoclonal antibody for pain relief in dogs | |
| RU2013153592A (ru) | Анти-mif антитела | |
| JP7776461B2 (ja) | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 | |
| RS56268B1 (sr) | Monoklonalno antitelo protiv interleukina-31 kod pasa | |
| IL271194B2 (en) | Anti-bcma heavy chain-only antibodies | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| JP2003519481A5 (https=) | ||
| JP2015509714A5 (https=) | ||
| JP2013520999A5 (https=) | ||
| EP3214442A1 (en) | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a | |
| CN101484180A (zh) | Cxcl13拮抗剂及其用于治疗炎性疾病的用途 | |
| JP2022545259A (ja) | 動物用の抗ｉｌ３１抗体 | |
| KR20230005875A (ko) | 수의학 용도를 위한 장시간-작용성 항-il31 항체 | |
| KR20230005880A (ko) | 수의학적 사용을 위한 il4/il13 수용체 분자 | |
| KR20260051047A (ko) | 인터루킨-31에 결합 가능한 항체 또는 이의 항원 결합 단편, 이의 제조 방법 및 응용 | |
| JP2008509152A5 (https=) | ||
| JP2012508027A5 (https=) | ||
| JP2015501146A5 (https=) | ||
| Woisetschläger et al. | In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her‐2/neu binding sites | |
| JPWO2021216899A5 (https=) | ||
| JPWO2021216810A5 (https=) |